Rankings
Pricing
Log In
Free Trial
US-listed companies
Verve Therapeutics, Inc.
Verve Therapeutics, Inc.
VERV
Market cap
$342.99M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2021
Dec 31,
2022
Net loss
-120
-157
Depreciation
2
3
Non-cash lease expense
2
4
Net amortization of premium (accretion of discount) on marketable securities
-
-1
Stock-based compensation
7
22
Change in fair value of antidilution rights
26
-
Change in fair value of success payments liabilities
8
-1
Collaboration receivable
-
1
Prepaid expenses and other current assets
8
9
Accounts payable
7
-5
Accrued expenses and other liabilities
6
7
Success of payment liability
-6
-
Deferred revenue
-
20
Operating lease liabilities
-2
-3
Net cash used in operating activities
-78
-122
Purchases of property and equipment
4
13
Purchases of marketable securities
371
479
Maturities of marketable securities
137
337
Net cash used in investing activities
-239
-156
Proceeds from issuance of Preferred Stock, net
94
-
Proceeds from Issuance Initial Public Offering
285
-
Proceeds from Issuance of Common Stock
-
40
Proceeds from issuance of common shares, net of commissions
-
287
Payment of equity offering costs
-
1
Proceeds from Stock Options Exercised
1
2
Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP
1
1
Net cash provided by financing activities
377
329
Increase (decrease) in cash, cash equivalents and restricted cash
60
51
Property and equipment additions included in accounts payable and accrued expenses
1
2
Conversion of convertible preferred stock to common stock upon closing of initial public offering
219
-
Settlement of derivative liability by issuing common stock
32
-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
1
83